Rodman & Renshaw initiated coverage on Athira Pharma with a new price target

8/19/24 8:48:03 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Rodman & Renshaw initiated coverage of Athira Pharma with a rating of Buy and set a new price target of $22.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ATHA

Date	Price Target	Rating	Analyst
9/19/2024	$5.00 → $0.50	Outperform → Neutral	Mizuho
9/4/2024		Buy → Neutral	Rodman & Renshaw
9/4/2024		Buy → Neutral	BTIG Research
9/4/2024		Mkt Outperform → Mkt Perform	JMP Securities
8/19/2024	$22.00	Buy	Rodman & Renshaw
10/17/2022	$20.00	Mkt Perform → Mkt Outperform	JMP Securities
7/7/2022	$6.00	Buy	Mizuho
6/23/2022	$36.00 → $5.00	Buy → Hold	Stifel